Arka Bagchi

@aiimskalyani.edu.in

Research Scientist
All India Institute of Medical Sciences Kalyani

Arka Bagchi


                           Download Compact PDF  
https://researchid.co/arkabagchi1993

EDUCATION

Ph.D., University of Kalyani, Kalyani, Nadia, West Bengal, India. Pin: 741235.
M.Sc. (Zoology), University of Kalyani, Kalyani, Nadia, West Bengal, India. Pin: 741235.

RESEARCH, TEACHING, or OTHER INTERESTS

Cancer Research, Gastroenterology, Molecular Biology, Biotechnology
21

Scopus Publications

216

Scholar Citations

9

Scholar h-index

9

Scholar i10-index

Scopus Publications

  • Correction to “Vesicle-Encapsulated Rolipram (PDE4 Inhibitor) and Its Anticancer Activity”
    Durga Mondal, Arka Bagchi, Sima Biswas, Tanmay Dagar, Arunima Biswas, Angshuman Bagchi, Swati De
    ACS Applied Bio Materials, 2026
  • Fecal microbiota transplantation in liver diseases: Therapeutic potential and associated risks
    Jayeeta Bhowmick, Arka Bagchi
    Progress in Molecular Biology and Translational Science, 2026
  • A multifaceted examination of the action of PDE4 inhibitor rolipram on MMP2/9 reveals therapeutic implications
    Arka Bagchi, Analabha Roy, Anindya Halder, Arunima Biswas
    Scientific Reports, 2025
    A PDE4 (phosphodiesterase 4) inhibitor, Rolipram, was previously found to down-regulate (in a manner dependent on cAMP (cyclic adenosine monophosphate)-PKA (protein kinase A)) MMP2 (matrix metalloproteinase 2) and MMP9 protein expression levels, important markers of epithelial-to-mesenchymal transition in human breast cancer cell lines. However, zymographic studies revealed that rolipram could also alter the enzymatic activities of these MMPs, even in the presence of the PKA inhibitor H89. This calls for more detailed investigations of the inhibitory mechanism of rolipram on MMP2 and MMP9. The prediction of ligand-based targets through online reverse screening indicated that proteases are likely targets of rolipram. Computational molecular docking also demonstrated significant binding affinities of rolipram for both MMP2 and MMP9 proteins. Concurrently, a well-known inhibitor of MMPs, SB3CT, was utilized as a positive control for this study. The best models of the docked complexes were used as initial conditions for molecular dynamics (MD) simulations to explore their dynamic behavior and stability. In particular, both the MMP2-rolipram and MMP9-rolipram complexes were found to be stable and compact for the duration of the simulation ([Formula: see text]). Several stable hydrogen bonds were also detected between the proteins and rolipram. In vitro experiments using primary cells from patients with breast cancer also showed that rolipram could alter the enzymatic activities of MMP2 and MMP9, independent of the cAMP-PKA signaling pathway, though it was thought to be cAMP-PKA dependent previously. These observations indicate the ability of rolipram to control breast cancer by regressing the functions of MMP2 and MMP9, thus having 'off-targets' other than PDE4 to have direct control over proteins that are involved in the advancement of metastasis.
  • In-silico drug repositioning studies of Candida albicans Nitrogen permease reactivator 1 (Npr1) kinase
    Sanjib Das, Arka Bagchi, Analava Bera, Arunima Biswas, Analabha Roy, Rik Ganguly, Amalesh Mondal, Deepanjan Chattopadhyay, Paromita Saha Mondal, Tanushree Mondal, Subhasree Samanta, Achintya Mohan Goswami, Tanima Saha
    Scientific Reports, 2025
    Npr1 is an essential protein in C. albicans, maintains ion homeostasis and nutrient transportation at cell membrane, and regulates the activity of ammonium transporter protein Mep2. Npr1 is one of the nine NPR/HAL family kinases classified under "Other groups" in C. albicans. In this study, we had performed protein homology modeling; structure based virtual screening of drugs, docking study and MD simulation. We employed drug repurposing pipeline from which 15 compounds were short listed. Among the compounds, Indacaterol was selected on the basis of high safety profile, binding affinity score value of - 9.3 kcal/mol, as well as its DFG-motif interaction. The best docked pose of the complex was utilized for MD simulation studies. The RMSD values from initial structure and protein-ligand complex were analyzed for the dynamic stability of drug-bound complex and compared with that of the apo-protein. The comparisons of average RMSF values show fluctuation within acceptable range, also very less change of Rg values occur between the protein and protein-ligand throughout the simulation. Further, the complex maintains on an average two hydrogen bonds throughout the simulation period. The binding stability of Npr1 and Indacaterol complex was also verified through Principal Component Analysis. The result secured from these computational approaches and techniques established that the drug has the potential to be developed as an anti-candida lead targeting candidiasis.
  • In vitro bio-physical interaction of Pd(II) complexes with DNA and BSA: Their molecular docking and anticancer property
    Angana Pan, Swarup Kumar Tarai, Arka Bagchi, Tarun Roy, Rituparna Bhaduri, Saikat Mandal, Karishma Singh, Monimala Das, Arunima Biswas, Sankar Chandra Moi
    Journal of Molecular Liquids, 2025
  • A systemic immunoinformatics approach to design combinatorial multiepitope vaccine candidates against vector-borne bacterial infections exploiting the proteomes of the causative agent and vector for scrub typhus
    Swarna Shaw, Arka Bagchi, Debyani Ruj, Sudipta Paul Bhattacharya, Arunima Biswas, Arijit Bhattacharya
    Microbe Netherlands, 2025
    An effective vaccine to prevent disease progression and transmission remains unavailable for most vector-borne bacterial infections. Recent comprehensive studies have explored not only the role of bacterial proteins in infection but also the significance of vector salivary proteins, underscoring the potential of combinatorial vaccines incorporating both bacterial and vector-derived antigens. Scrub typhus (ST), caused by the bacterium Orientia tsutsugamushi , is a mite-borne infection and a significant public health concern in eastern and southeastern Asia. Similar to other vector-borne bacterial diseases, the lack of an effective vaccine hampers prophylaxis against ST. Vaccine development is particularly challenging due to the extreme genetic diversity of major surface antigens, which limits cross-protection. In this study, a proteome-wide immunoinformatic approach was employed to identify immunodominant outer membrane proteins of O. tsutsugamushi , mapping conserved regions enriched in B-cell, Tc-cell, and Th-cell epitopes. Additionally, immunodominant regions from vector salivary proteins were identified. Using these segments, fifteen multi-epitope vaccines (MEVs) were designed and assessed for their physicochemical and immunological properties. The tertiary structure of the prioritized MEV was modelled, and its interactions with Toll-like receptors (TLR2, TLR4, and TLR5) were analyzed through molecular docking and molecular dynamics (MD) simulations. A glycosylation-deficient variant of the MEV was also designed and evaluated using the same methods. Immune simulations suggested that both MEVs could elicit a strong immune response. Furthermore, in silico cloning and expression analyses were conducted for bacterial expression system. While the proteome-wide combinatorial approach using immunodominant segments shows promise, experimental validation is necessary to confirm its efficacy against ST and other vector-borne bacterial infections. Strategy to configure a multiepitope vaccine for scrub typhus exploiting bacterial proteme and salivary proteome of the insect vector. • There is lack of an effective vaccine for Scrub typhus, a significant public health concern in eastern and southeastern Asia. • A strategy was adopted to identify immunodominant proteins and segments from bacterial proteome and salivary proteome of the insect vector. • 15 multiepitope vaccines (MEV) were configured by combining the immunodominant segments and evaluated to prioritize the most potent MEV. • Structural analysis and immune simulation highlighted prospect of the MEV to get translated in to an effective vaccine.
  • Amino-Terephthalonitrile Based Single Benzene Fluorophores Bearing Amino Esters and Lipids for Selective Biothiol Sensing and Bioimaging
    Ankita Sinha, Subhadeep Banerjee, Arka Bagchi, Sumiran Kasturi, Arnab Banerjee
    Asian Journal of Organic Chemistry, 2025
    We report here the preparation of eight new AmTN SBFs which feature amino esters with an N‐terminal fluorophore and also lipophilic dyes, consisting of a push‐pull AmTN moiety. Spectrofluorimetric and NMR titration investigations reveal the preference of the terephthalonitirle ring in mono AmTNs towards rapid sensing of N‐acetyl cysteine, as opposed to the dipeptide carnosine. This has significance in the field of bioanalysis whereby the AmTNs could show their potential as thiol sensing platforms. Also, one of the lipophilic green emissive AmTNs featuring two cyclohexyl units proved its worth in fluorescence imaging using C2 C12 cells, where it localized electively inside the cell cytoplasm at concentration of 1 μM.
  • Phosphodiesterase 4 as a candidate therapeutic target of cancer
    Arka Bagchi, Arunima Biswas
    Indian Journal of Biochemistry and Biophysics, 2025
    In this review, we explore the potential of cAMP-Phosphodiesterase 4 (PDE4), a key intracellular enzyme, as a therapeutic target for cancer treatment. cAMP-PDEs play a critical role in regulating intracellular levels of cyclic adenosine monophosphate (cAMP), an essential second messenger involved in cell proliferation and metastasis in a tissue-specific manner depending on the PDE isoforms present. Elevated PDE4 expression has been reported in cancers such as breast, cervical, and lung cancer. Specific PDE4 subtypes are recognized for their roles in cancer progression, making PDE4 inhibitors promising candidates for therapeutic intervention. This review examines the role of PDE4 in cancer progression and highlights the therapeutic potential of studied PDE4 inhibitors.
  • PDE4 inhibitor rolipram represses hedgehog signaling via ubiquitin-mediated proteolysis of GLI transcription factors to regress breast cancer
    Arka Bagchi, Anuran Bhattacharya, Analava Bera, Deblina Basak, Urmi Chatterji, Arunima Biswas
    Journal of Biological Chemistry, 2025
    Aberrant activation of the Hedgehog (Hh) signaling pathway positively correlates with progression, invasion, and metastasis of several cancers, including breast cancer. Although numerous inhibitors of the Hh signaling pathway are available, several oncogenic mutations of key components of the pathway, including Smoothened, have limited their capability to be developed as putative anticancer drugs. In this study, we have modulated the Hh signaling pathway in breast cancer using a specific Food and Drug Administration-approved phosphodiesterase 4 inhibitor rolipram. The results indicated that increased levels of cAMP-dependent PKA, because of the treatment with rolipram on MCF-7 and MDA-MB-231 cells, induced PKA-mediated ubiquitination of glioma-associated oncogene homolog 2 full length (GLI2FL) and GLI3FL, leading to their transformation to respective repressor forms. This in turn reduced the level of GLI1 (glioma-associated oncogene homolog 1) transcription factor in a time-dependent manner. We have also shown that elevated levels of PKA reduced the level of phosphorylated glycogen synthase kinase 3β, which is known to augment PKA-mediated ubiquitination of GLI2FL and GLI3FL. Rolipram treatment also impaired wound healing and migration in both cell lines and significantly reduced tumor weight and volume in tumor-bearing mice. Histological analysis showed a reduction in multinucleated cells and cellular infiltration in the lungs of rolipram-treated mice. Moreover, rolipram decreased GLI1 levels in tumors by enhancing cAMP-PKA signaling. These findings suggest that rolipram effectively inhibits the Hh pathway downstream of Smoothened, offering potential as a therapeutic strategy for controlling breast cancer progression and metastasis, including both hormone-responsive and triple-negative subtypes.
  • Repurposing approved protein kinase inhibitors as potent anti-leishmanials targeting Leishmania MAP kinases
    Anindita Bhattacharjee, Arka Bagchi, Solanki Sarkar, Sriparna Bawali, Arijit Bhattacharya, Arunima Biswas
    Life Sciences, 2024
  • Synthesis, Spectroscopy and Structural Elucidation of Two new CoII and NiII Complexes of Pyrazole Derived Heterocyclic Schiff base ligand as Potential Anticancer and Photocatalytic Agents
    Suman Mandal, Arka Bagchi, Arunima Biswas, David B. Cordes, Alexandra M. Z. Slawin, Nitis Chandra Saha
    Chemistry Africa, 2024
  • Vesicle-Encapsulated Rolipram (PDE4 Inhibitor) and Its Anticancer Activity
    Durga Mondal, Arka Bagchi, Sima Biswas, Tanmay Dagar, Arunima Biswas, Angshuman Bagchi, Swati De
    ACS Applied Bio Materials, 2024
  • Catalytic and anticancer activity of two new Ni(II) complexes with a pyrazole based heterocyclic Schiff-base ligand: Synthesis, spectroscopy and X-ray crystallography
    Suman Mandal, Mitali Sarkar, Shanku Denrah, Arka Bagchi, Arunima Biswas, David B. Cordes, Alexandra M.Z. Slawin, Nitis Chandra Saha
    Journal of Molecular Structure, 2023
  • Biophysical study on DNA and BSA binding activity of Cu(II) complex: Synthesis, molecular docking, cytotoxic activity, and theoretical approach
    Swarup Kumar Tarai, Saikat Mandal, Arup Tarai, Ipsita Som, Angana Pan, Arka Bagchi, Arunima Biswas, Sankar Ch. Moi
    Applied Organometallic Chemistry, 2023
  • Cytotoxic behavior and DNA/BSA binding activity of thiosemicarbazone based Ni(II) complex: bio-physical, molecular docking and DFT study
    Swarup Kumar Tarai, Arup Tarai, Saikat Mandal, Bhaskar Nath, Ipsita Som, Rituparna Bhaduri, Arka Bagchi, Solanki Sarkar, Arunima Biswas, Sankar Ch. Moi
    Journal of Molecular Liquids, 2023
  • Photophysical study on DNA & BSA binding and cytotoxic behaviour of piperidine-Pt(II) complexes: Their kinetics & mechanism and molecular docking
    Angana Pan, Rituparna Bhaduri, Saikat Mandal, Swarup Kumar Tarai, Arka Bagchi, Arunima Biswas, Sankar Ch. Moi
    Journal of Photochemistry and Photobiology A Chemistry, 2023
  • PDE4 inhibitor eliminates breast cancer stem cells via noncanonical activation of mTOR
    Pritha Mukherjee, Arka Bagchi, Ananya Banerjee, Himansu Roy, Arijit Bhattacharya, Arunima Biswas, Urmi Chatterji
    Journal of Cellular Biochemistry, 2022
  • In vitro anticancer activity of Pd(II) complexes with pyridine scaffold: Their bioactivity, role in cell cycle arrest, and computational study
    Rituparna Bhaduri, Angana Pan, Swarup Kumar Tarai, Saikat Mandal, Arka Bagchi, Arunima Biswas, Sankar Ch. Moi
    Journal of Molecular Liquids, 2022
  • Cytotoxic activity of nitrogen, sulfur, and oxygen chelated Pt(II) complexes; their DNA/BSA binding by in vitro and in silico approaches
    Rituparna Bhaduri, Saikat Mandal, Swarup Kumar Tarai, Angana Pan, Subhajit Mukherjee, Arka Bagchi, Arunima Biswas, Sankar Ch. Moi
    Journal of Molecular Liquids, 2022
  • Application of MOFs and Their Derived Materials in Molecular Transport
    Arka Bagchi, Partha Saha, Arunima Biswas, SK Manirul Islam
    Applications of Metal Organic Frameworks and their Derived Materials, 2020
  • Toxicological evaluations of nanocomposites with special reference to cancer therapy
    Arpita Hazra Chowdhury, Arka Bagchi, Arunima Biswas, Sk. Manirul Islam
    Sustainable Polymer Composites and Nanocomposites, 2019

RECENT SCHOLAR PUBLICATIONS

  • Correction to “Vesicle-Encapsulated Rolipram (PDE4 Inhibitor) and Its Anticancer Activity”
    D Mondal, A Bagchi, S Biswas, T Dagar, A Biswas, A Bagchi, S De
    ACS Applied Bio Materials , 2026
    2026
  • Anticancer Activity of Picolinamide and Sulfur Chelated Pt (II) Complexes Against Breast Cancer: In Vitro Interaction Studies Through Molecular Docking With Bio‐Receptors
    S Chatterjee, S Mandal, C Das, R Bhaduri, A Bagchi, A Biswas, SC Moi
    Chemistry–An Asian Journal 21 (2), e70593 , 2026
    2026
  • In vitro bio-physical interaction of Pd (II) complexes with DNA and BSA: Their molecular docking and anticancer property
    A Pan, SK Tarai, A Bagchi, T Roy, R Bhaduri, S Mandal, K Singh, M Das, ...
    Journal of Molecular Liquids, 128468 , 2025
    2025
    Citations: 2
  • In-silico drug repositioning studies of Candida albicans Nitrogen permease reactivator 1 (Npr1) kinase
    S Das, A Bagchi, A Bera, A Biswas, A Roy, R Ganguly, A Mondal, ...
    Scientific Reports 15 (1), 23626 , 2025
    2025
    Citations: 2
  • A systemic immunoinformatics approach to design combinatorial multiepitope vaccine candidates against vector-borne bacterial infections exploiting the proteomes of the …
    S Shaw, A Bagchi, D Ruj, SP Bhattacharya, A Biswas, A Bhattacharya
    The Microbe 7, 100324 , 2025
    2025
    Citations: 1
  • Amino‐Terephthalonitrile Based Single Benzene Fluorophores Bearing Amino Esters and Lipids for Selective Biothiol Sensing and Bioimaging
    A Sinha, S Banerjee, A Bagchi, S Kasturi, A Banerjee
    Asian Journal of Organic Chemistry 14 (5), e202500040 , 2025
    2025
    Citations: 2
  • A multifaceted examination of the action of PDE4 inhibitor rolipram on MMP2/9 reveals therapeutic implications
    A Bagchi, A Roy, A Halder, A Biswas
    Scientific Reports 15 (1), 10963 , 2025
    2025
    Citations: 1
  • PDE4 inhibitor rolipram represses hedgehog signaling via ubiquitin-mediated proteolysis of GLI transcription factors to regress breast cancer
    A Bagchi, A Bhattacharya, A Bera, D Basak, U Chatterji, A Biswas
    Journal of Biological Chemistry 301 (3), 108239 , 2025
    2025
    Citations: 11
  • Phosphodiesterase 4 as a candidate therapeutic target of cancer
    A Bagchi, A Biswas
    Indian Journal of Biochemistry and Biophysics (IJBB) 62 (3), 213-221 , 2025
    2025
  • Repurposing approved protein kinase inhibitors as potent anti-leishmanials targeting Leishmania MAP kinases
    A Bhattacharjee, A Bagchi, S Sarkar, S Bawali, A Bhattacharya, A Biswas
    Life Sciences 351, 122844 , 2024
    2024
    Citations: 15
  • The Hidden Potential of PDE4 Inhibitor Rolipram: A Multifaceted Examination of its Inhibition of MMP2/9 Reveals Therapeutic Implications
    A Bagchi, A Roy, A Halder, A Biswas
    bioRxiv, 2024.05. 16.594542 , 2024
    2024
    Citations: 1
  • Synthesis, Spectroscopy and Structural Elucidation of Two new Co II and Ni II Complexes of Pyrazole Derived Heterocyclic Schiff base ligand as Potential …
    S Mandal, A Bagchi, A Biswas, DB Cordes, AMZ Slawin, NC Saha
    Chemistry Africa 7 (3), 1211-1221 , 2024
    2024
    Citations: 2
  • Designing Combinatorial Multiepitope Vaccine Candidates against Scrub Typus by a Proteome-wide Immunoinfomatics Approach
    S Shaw, A Bagchi, D Ruj, SP Bhattacharya, A Biswas, A Bhattacharya
    bioRxiv, 2024.03. 05.583536 , 2024
    2024
  • Vesicle-encapsulated rolipram (Pde4 inhibitor) and its anticancer activity
    D Mondal, A Bagchi, S Biswas, T Dagar, A Biswas, A Bagchi, S De
    ACS Applied Bio Materials 7 (1), 369-378 , 2023
    2023
    Citations: 5
  • Catalytic and anticancer activity of two new Ni (II) complexes with a pyrazole based heterocyclic Schiff-base ligand: Synthesis, spectroscopy and X-ray crystallography
    S Mandal, M Sarkar, S Denrah, A Bagchi, A Biswas, DB Cordes, ...
    Journal of Molecular Structure 1287, 135648 , 2023
    2023
    Citations: 22
  • Biophysical study on DNA and BSA binding activity of Cu (II) complex: Synthesis, molecular docking, cytotoxic activity, and theoretical approach
    SK Tarai, S Mandal, A Tarai, I Som, A Pan, A Bagchi, A Biswas, SC Moi
    Applied Organometallic Chemistry 37 (8), e7164 , 2023
    2023
    Citations: 15
  • Cytotoxic behavior and DNA/BSA binding activity of thiosemicarbazone based Ni (II) complex: bio-physical, molecular docking and DFT study
    SK Tarai, A Tarai, S Mandal, B Nath, I Som, R Bhaduri, A Bagchi, S Sarkar, ...
    Journal of Molecular Liquids 383, 121921 , 2023
    2023
    Citations: 30
  • Photophysical study on DNA & BSA binding and cytotoxic behaviour of piperidine-Pt (II) complexes: Their kinetics & mechanism and molecular docking
    A Pan, R Bhaduri, S Mandal, SK Tarai, A Bagchi, A Biswas, SC Moi
    Journal of Photochemistry and Photobiology A: Chemistry 441, 114740 , 2023
    2023
    Citations: 6
  • In vitro anticancer activity of Pd (II) complexes with pyridine scaffold: Their bioactivity, role in cell cycle arrest, and computational study
    R Bhaduri, A Pan, SK Tarai, S Mandal, A Bagchi, A Biswas, SC Moi
    Journal of Molecular Liquids 367, 120540 , 2022
    2022
    Citations: 17
  • PDE 4 inhibitor eliminates breast cancer stem cells via non-canonical activation of mTOR
    UC Pritha Mukkherjee, Arka Bagchi, Ananya Banerjee, Arijit Bhattacharya ...
    Journal of Cellular Biochemistry 2022, 1-17 , 2022
    2022
    Citations: 26

MOST CITED SCHOLAR PUBLICATIONS

  • Melanotic spinal schwannoma.
    AK Bagchi, SK Sarkar, DP Chakraborti
    Surgical Neurology 3 (2), 79-81 , 1975
    1975
    Citations: 37
  • Cytotoxic behavior and DNA/BSA binding activity of thiosemicarbazone based Ni (II) complex: bio-physical, molecular docking and DFT study
    SK Tarai, A Tarai, S Mandal, B Nath, I Som, R Bhaduri, A Bagchi, S Sarkar, ...
    Journal of Molecular Liquids 383, 121921 , 2023
    2023
    Citations: 30
  • PDE 4 inhibitor eliminates breast cancer stem cells via non-canonical activation of mTOR
    UC Pritha Mukkherjee, Arka Bagchi, Ananya Banerjee, Arijit Bhattacharya ...
    Journal of Cellular Biochemistry 2022, 1-17 , 2022
    2022
    Citations: 26
  • Catalytic and anticancer activity of two new Ni (II) complexes with a pyrazole based heterocyclic Schiff-base ligand: Synthesis, spectroscopy and X-ray crystallography
    S Mandal, M Sarkar, S Denrah, A Bagchi, A Biswas, DB Cordes, ...
    Journal of Molecular Structure 1287, 135648 , 2023
    2023
    Citations: 22
  • In vitro anticancer activity of Pd (II) complexes with pyridine scaffold: Their bioactivity, role in cell cycle arrest, and computational study
    R Bhaduri, A Pan, SK Tarai, S Mandal, A Bagchi, A Biswas, SC Moi
    Journal of Molecular Liquids 367, 120540 , 2022
    2022
    Citations: 17
  • Cytotoxic activity of nitrogen, sulfur, and oxygen chelated Pt (II) complexes; their DNA/BSA binding by in vitro and in silico approaches
    R Bhaduri, S Mandal, SK Tarai, A Pan, S Mukherjee, A Bagchi, A Biswas, ...
    Journal of Molecular Liquids 360, 119529 , 2022
    2022
    Citations: 16
  • Repurposing approved protein kinase inhibitors as potent anti-leishmanials targeting Leishmania MAP kinases
    A Bhattacharjee, A Bagchi, S Sarkar, S Bawali, A Bhattacharya, A Biswas
    Life Sciences 351, 122844 , 2024
    2024
    Citations: 15
  • Biophysical study on DNA and BSA binding activity of Cu (II) complex: Synthesis, molecular docking, cytotoxic activity, and theoretical approach
    SK Tarai, S Mandal, A Tarai, I Som, A Pan, A Bagchi, A Biswas, SC Moi
    Applied Organometallic Chemistry 37 (8), e7164 , 2023
    2023
    Citations: 15
  • PDE4 inhibitor rolipram represses hedgehog signaling via ubiquitin-mediated proteolysis of GLI transcription factors to regress breast cancer
    A Bagchi, A Bhattacharya, A Bera, D Basak, U Chatterji, A Biswas
    Journal of Biological Chemistry 301 (3), 108239 , 2025
    2025
    Citations: 11
  • Photophysical study on DNA & BSA binding and cytotoxic behaviour of piperidine-Pt (II) complexes: Their kinetics & mechanism and molecular docking
    A Pan, R Bhaduri, S Mandal, SK Tarai, A Bagchi, A Biswas, SC Moi
    Journal of Photochemistry and Photobiology A: Chemistry 441, 114740 , 2023
    2023
    Citations: 6
  • Vesicle-encapsulated rolipram (Pde4 inhibitor) and its anticancer activity
    D Mondal, A Bagchi, S Biswas, T Dagar, A Biswas, A Bagchi, S De
    ACS Applied Bio Materials 7 (1), 369-378 , 2023
    2023
    Citations: 5
  • Application of microbes in vaccine production
    A Bagchi, P Saha, A Biswas, SM Islam
    Application of Microbes in Environmental and Microbial Biotechnology, 573-585 , 2022
    2022
    Citations: 4
  • In vitro bio-physical interaction of Pd (II) complexes with DNA and BSA: Their molecular docking and anticancer property
    A Pan, SK Tarai, A Bagchi, T Roy, R Bhaduri, S Mandal, K Singh, M Das, ...
    Journal of Molecular Liquids, 128468 , 2025
    2025
    Citations: 2
  • In-silico drug repositioning studies of Candida albicans Nitrogen permease reactivator 1 (Npr1) kinase
    S Das, A Bagchi, A Bera, A Biswas, A Roy, R Ganguly, A Mondal, ...
    Scientific Reports 15 (1), 23626 , 2025
    2025
    Citations: 2
  • Amino‐Terephthalonitrile Based Single Benzene Fluorophores Bearing Amino Esters and Lipids for Selective Biothiol Sensing and Bioimaging
    A Sinha, S Banerjee, A Bagchi, S Kasturi, A Banerjee
    Asian Journal of Organic Chemistry 14 (5), e202500040 , 2025
    2025
    Citations: 2
  • Synthesis, Spectroscopy and Structural Elucidation of Two new Co II and Ni II Complexes of Pyrazole Derived Heterocyclic Schiff base ligand as Potential …
    S Mandal, A Bagchi, A Biswas, DB Cordes, AMZ Slawin, NC Saha
    Chemistry Africa 7 (3), 1211-1221 , 2024
    2024
    Citations: 2
  • A systemic immunoinformatics approach to design combinatorial multiepitope vaccine candidates against vector-borne bacterial infections exploiting the proteomes of the …
    S Shaw, A Bagchi, D Ruj, SP Bhattacharya, A Biswas, A Bhattacharya
    The Microbe 7, 100324 , 2025
    2025
    Citations: 1
  • A multifaceted examination of the action of PDE4 inhibitor rolipram on MMP2/9 reveals therapeutic implications
    A Bagchi, A Roy, A Halder, A Biswas
    Scientific Reports 15 (1), 10963 , 2025
    2025
    Citations: 1
  • The Hidden Potential of PDE4 Inhibitor Rolipram: A Multifaceted Examination of its Inhibition of MMP2/9 Reveals Therapeutic Implications
    A Bagchi, A Roy, A Halder, A Biswas
    bioRxiv, 2024.05. 16.594542 , 2024
    2024
    Citations: 1
  • MXenes for biomedical applications
    A Bagchi
    Materials Research Foundations 51 , 2019
    2019
    Citations: 1